Cargando…
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Ph-positive leukemias. At a once-daily dose and a relatively short half-life of 3-5 hours, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or l...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038787/ https://www.ncbi.nlm.nih.gov/pubmed/20111071 http://dx.doi.org/10.1038/leu.2009.302 |